Stock listing

Munich:B9A BioArctic AB Aktie

German listing (Munich) of BioArctic AB · home listing Stockholm:BIOAB

Follow BioArctic AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:BIOA_B

289.00 SEK +1.60 (+0.6%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:BIOA_B

Since Jul 7, 2026 -10.4% · daily closes, Jul 7, 2026 – Oct 19, 2026, adjusted for splits
Day range
283.20 – 290.40 SEKOct 19, 2026
Volume
94,156 sharesOct 19, 2026
Market value
25.65B SEKAt the close on Oct 19, 2026 · price × 88.74M shares outstanding
BioArctic AB logo
Ticker
Munich:B9A
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Bioarctic (Stockholm:BIOA B) Q2 2026 Earnings Call

    Wed, Aug 26, 2026 · 3:30 AM ET

    Watch Transcript

  • Bioarctic (Stockholm:BIOA B) Q1 2026 Earnings Call

    Wed, May 20, 2026 · 1:00 AM ET

    Watch Transcript

  • Bioarctic (Stockholm:BIOA B) Q4 2025 Earnings Call

    Wed, Feb 18, 2026 · 3:30 AM ET

    Watch Transcript

Latest news

BioArctic publishes the Annual Report and Sustainability Report for 2025

Apr 21, 2026

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

Mar 27, 2026

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Mar 11, 2026

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

Feb 27, 2026

Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET

Feb 11, 2026

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Feb 9, 2026

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Feb 6, 2026

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

Jan 26, 2026

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

Jan 25, 2026

BLA for subcutaneous formulation of Leqembi® accepted in China

Jan 6, 2026

All BioArctic AB news

Decks

BioArctic AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 31 in all · newest Apr 21, 2026 · oldest 2025
Calls
14 calls with a replay · 14 with a transcript · latest Aug 26, 2026
Decks
10 decks · latest Aug 26, 2026

Where BioArctic AB is listed

ListingExchangeCountryCurrency
Stockholm:BIOAB · Home listingStockholmSwedenSEK
gettex:B9AgettexGermanyEUR
LSIN:0RV2LSINUnited KingdomSEK
Aquis:BIOABSAquisUnited KingdomSEK
OTC:BRCTFOTCUnited StatesUSD
LS Exchange:A2H5GSLS ExchangeGermanyEUR
Lang & Schwarz:A2H5GSLang & SchwarzGermanyEUR
Tradegate:B9ATradegateGermanyEUR
Frankfurt:B9AFrankfurtGermanyEUR
Hamburg:B9AHamburgGermanyEUR
Aquis:BIOABSAquisUnited KingdomSEK
Dusseldorf:B9ADusseldorfGermanyEUR
Munich:B9A · This pageMunichGermanyEUR
Stuttgart:B9AStuttgartGermanyEUR
Turquoise:BIOABSTurquoiseUnited KingdomSEK

Log in to ask 6ix AI your own questions about BioArctic AB.